Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18405787 | EFFECTIVE ANTICANCER DRUG CANDIDATE OF DINUCLEAR PALLADIUM (II) BIS-DIHYDROZONE MALONYL COMPLEX | January 2024 | April 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18526686 | NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENS | December 2023 | July 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18378758 | 6'-(4-CHLOROPHENYL)-2'-ALKOXY-3,4'-BIPYRIDINE-3'- CARBONITRILES AS ANTIMICROBIAL COMPOUNDS | October 2023 | March 2024 | Allow | 5 | 1 | 1 | Yes | No |
| 18447620 | PHARMACEUTICAL COMPOSITIONS OF TOFACITINIB FOR ORAL ADMINISTRATION | August 2023 | December 2023 | Allow | 4 | 1 | 0 | Yes | No |
| 18189073 | NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENS | March 2023 | April 2024 | Allow | 13 | 2 | 0 | Yes | No |
| 18177640 | SYSTEMS AND METHODS FOR DELIVERY OF PHENYLALANINE AND LACTATE | March 2023 | August 2024 | Abandon | 18 | 2 | 1 | No | No |
| 18171431 | ANALGESIC AND ANTIPRURITIC PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | February 2023 | November 2023 | Allow | 9 | 1 | 0 | Yes | No |
| 18170804 | TOPICAL PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST AMITRIPTYLINE, FOR THE TREATMENT OF PERIPHERAL NEUROPATHIC PAIN | February 2023 | September 2024 | Abandon | 19 | 1 | 0 | No | No |
| 18160874 | PHARMACEUTICAL COMPOSITIONS FOR TREATING PAIN | January 2023 | November 2023 | Allow | 10 | 1 | 1 | Yes | No |
| 18096794 | MOLECULES, FORMULATIONS, AND METHODS FOR NUTRITIONAL SUPPORT OF ATHLETES, PATIENTS, AND OTHERS | January 2023 | April 2024 | Allow | 15 | 2 | 1 | Yes | No |
| 18153870 | NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENS | January 2023 | August 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 17982909 | COMPOSITIONS FOR TOPICAL TREATMENT OF RADIATION DERMATITIS | November 2022 | March 2024 | Allow | 17 | 4 | 1 | Yes | No |
| 17998098 | TREATMENT OF SKIN CONDITIONS USING HIGH KRAFFT TEMPERATURE ANIONIC SURFACTANTS | November 2022 | December 2023 | Abandon | 13 | 1 | 0 | No | No |
| 17976660 | TOPICAL OPHTHALMOLOGICAL COMPOSITIONS | October 2022 | January 2024 | Allow | 14 | 2 | 1 | Yes | No |
| 17961943 | STABLE PHARMACEUTICAL COMPOSITIONS OF CYCLOPHOSPHAMIDE | October 2022 | December 2023 | Allow | 14 | 2 | 1 | Yes | No |
| 17929569 | TOPICAL FORMULATIONS CONTAINING MTOR INHIBITORS | September 2022 | October 2023 | Allow | 13 | 2 | 1 | Yes | No |
| 17901284 | STABLE FORMULATIONS COMPRISING THIOTEPA | September 2022 | March 2024 | Allow | 18 | 2 | 1 | Yes | No |
| 17822756 | STABLE PHARMACEUTICAL COMPOSITIONS OF SUCCINYLCHOLINE CHLORIDE | August 2022 | August 2023 | Allow | 12 | 2 | 1 | Yes | No |
| 17881191 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPIOID OVERDOSE | August 2022 | September 2023 | Allow | 13 | 1 | 0 | No | No |
| 17879838 | ORAL PHARMACEUTICAL SOLUTION OF CLOPIDOGREL | August 2022 | November 2023 | Abandon | 15 | 2 | 1 | No | No |
| 17861054 | COMPOSITIONS AND METHODS COMPRISING SANSHOOL AS LIP INTERACTING COMPONENTS | July 2022 | September 2023 | Allow | 14 | 2 | 2 | Yes | No |
| 17808234 | SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION | June 2022 | June 2023 | Allow | 12 | 0 | 0 | No | No |
| 17836560 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | June 2022 | December 2022 | Allow | 6 | 1 | 0 | Yes | No |
| 17745378 | Aqueous Suspensions of TMC278 | May 2022 | May 2024 | Allow | 24 | 2 | 0 | Yes | No |
| 17716505 | AMLODIPINE FORMULATIONS | April 2022 | May 2024 | Allow | 26 | 0 | 0 | Yes | No |
| 17712524 | STABLE PHARMACEUTICAL FORMULATION | April 2022 | January 2023 | Allow | 10 | 2 | 0 | Yes | No |
| 17704168 | TOPICAL FORMULATION FOR A JAK INHIBITOR | March 2022 | October 2022 | Allow | 7 | 2 | 0 | Yes | No |
| 17557626 | COMPOSITIONS OF BILE ACIDS AND PHENYLBUTYRATE COMPOUNDS | December 2021 | September 2022 | Allow | 9 | 1 | 1 | Yes | No |
| 17535830 | COMPOSITIONS FOR USE IN SURGERY | November 2021 | May 2024 | Abandon | 30 | 1 | 1 | No | No |
| 17492377 | TOPICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY SKIN DISEASES | October 2021 | September 2024 | Abandon | 36 | 2 | 1 | No | No |
| 17467207 | OIL-IN-WATER TYPE DERMATOLOGICAL COMPOSITION FOR EXTERNAL USE | September 2021 | June 2024 | Allow | 33 | 2 | 0 | No | No |
| 17403800 | Reversal of General Anesthesia by Administration of Methylphenidate, Amphetamine, Modafinil, Amantadine, and/or Caffeine | August 2021 | January 2024 | Abandon | 29 | 1 | 0 | No | No |
| 17396951 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ADDICTION AND OTHER NEUROPSYCHIATRIC DISORDERS | August 2021 | December 2023 | Abandon | 28 | 0 | 1 | No | No |
| 17391808 | ANXIOLYTIC COMPOSITION, FORMULATION AND METHOD OF USE | August 2021 | April 2024 | Abandon | 32 | 1 | 1 | No | No |
| 17366668 | COMPOSITION AND METHOD FOR TREATING INFECTIONS | July 2021 | October 2023 | Abandon | 27 | 4 | 1 | No | No |
| 17358966 | TREATMENT FOR PROGRESSIVE MULTIPLE SCLEROSIS | June 2021 | May 2024 | Abandon | 35 | 2 | 0 | No | No |
| 17352336 | Anthocyanin and Quercetin Based Formulations for Improved Respiratory Health | June 2021 | December 2023 | Abandon | 30 | 1 | 0 | No | No |
| 17344314 | METHODS OF TREATING A PATIENT HAVING PARKINSON'S DISEASE | June 2021 | May 2023 | Abandon | 23 | 2 | 1 | Yes | No |
| 17344415 | STABLE ORGANIC CANNABINOID OIL BLEND FORMULATIONS | June 2021 | October 2022 | Abandon | 16 | 0 | 1 | No | No |
| 17326922 | Parenteral Formulations of Dopamine Agonists | May 2021 | February 2024 | Abandon | 33 | 1 | 0 | No | No |
| 17293941 | USE OF BULLEYACONITINE A | May 2021 | March 2024 | Allow | 34 | 0 | 0 | Yes | No |
| 17314281 | Dosing Regimens Associated With Extended Release Paliperidone Injectable Formulations | May 2021 | February 2022 | Allow | 9 | 1 | 1 | Yes | No |
| 17314274 | TOPICAL REGIONAL NEURO-AFFECTIVE THERAPY | May 2021 | October 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17245085 | BIOAVAILABLE MINERALS FOR THE MITIGATION OF CORONA VIRUSES (COVID 19), MANUFACTURING METHOD AND A TREATMENT METHOD | April 2021 | January 2024 | Abandon | 32 | 0 | 1 | No | No |
| 17239007 | PHARMACEUTICAL COMPOSITIONS OF TOFACITINIB FOR ORAL ADMINISTRATION | April 2021 | August 2023 | Allow | 27 | 4 | 1 | Yes | No |
| 17217311 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | March 2021 | February 2022 | Allow | 10 | 1 | 1 | Yes | No |
| 17249917 | METHODS FOR TREATING ACNE | March 2021 | December 2023 | Abandon | 33 | 0 | 1 | No | No |
| 17194016 | AMLODIPINE FORMULATIONS | March 2021 | February 2022 | Allow | 11 | 2 | 1 | Yes | No |
| 17194146 | TOPICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY SKIN DISEASES | March 2021 | September 2021 | Allow | 6 | 1 | 1 | Yes | No |
| 17184353 | Therapeutic Terpene Formulations | February 2021 | December 2023 | Abandon | 33 | 0 | 1 | No | No |
| 17178156 | ANTIVIRAL COMPOUNDS | February 2021 | March 2024 | Allow | 37 | 3 | 1 | Yes | No |
| 17158464 | METHODS OF MODULATING TETRABENAZINE METABOLITES PLASMA LEVELS USING BUPROPION | January 2021 | April 2022 | Abandon | 15 | 2 | 0 | No | No |
| 17158392 | NON-CRYSTALLIZING CANNABIDIOL BLENDS | January 2021 | January 2023 | Allow | 24 | 2 | 1 | Yes | No |
| 17156671 | ANTIBIOTIC GEL FORMULATION AND METHODS OF PREPARING THE ANTIBIOTIC GEL FORMULATION | January 2021 | November 2023 | Abandon | 33 | 0 | 1 | No | No |
| 17108679 | Parenteral Formulation | December 2020 | November 2022 | Abandon | 23 | 0 | 0 | No | No |
| 15734068 | SYNERGIC PHARMACEUTICAL COMPOSITION OF THE ACTIVE ENANTIOMER (S)-KETOROLAC AND GABAPENTIN FOR THE TREATMENT OF NEUROPATHIC PAIN | December 2020 | September 2022 | Allow | 21 | 2 | 1 | Yes | No |
| 17100758 | METHODS FOR TREATING NEUROLOGICAL DISORDERS WITH a1A-AR PARTIAL AGONISTS | November 2020 | June 2023 | Abandon | 31 | 3 | 2 | Yes | No |
| 16950654 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | November 2020 | July 2023 | Allow | 32 | 1 | 1 | Yes | No |
| 17095391 | METHODS OF TREATING PEDIATRIC PATIENTS USING DEXMEDETOMIDINE | November 2020 | July 2023 | Abandon | 32 | 1 | 0 | No | No |
| 17094233 | PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF INFLAMMATORY CHANGES TO THE RECTUM | November 2020 | April 2023 | Allow | 29 | 1 | 0 | Yes | No |
| 17088871 | OXYMETAZOLINE FOR THE TREATMENT OF ANO-RECTAL DISORDERS | November 2020 | July 2023 | Abandon | 33 | 1 | 0 | No | No |
| 17080360 | nAChR-alpha7 Agonists and nAChR-alpha7 Antagonists for Treating Ulcerative Colitis (UC) and Crohn's Disease (CD) | October 2020 | April 2024 | Abandon | 42 | 2 | 0 | Yes | No |
| 17072923 | TOPICAL PHARMACEUTICAL COMPOSITION BASED ON SEMIFLUORINATED ALKANES | October 2020 | July 2023 | Allow | 33 | 2 | 1 | No | No |
| 17064759 | USE OF LEVODOPA, CARBIDOPA AND ENTACAPONE FOR TREATING PARKINSON'S DISEASE | October 2020 | May 2023 | Allow | 32 | 1 | 1 | Yes | No |
| 17045339 | Method of administering a Medication | October 2020 | May 2024 | Abandon | 44 | 0 | 1 | No | No |
| 17039769 | ILOPERIDONE METABOLITE FOR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | September 2020 | December 2023 | Abandon | 38 | 2 | 1 | No | No |
| 17043521 | SULFONAMIDE-CONTAINING 4-(N-METHYL) AMINOPIPERIDINE MYRICETIN DERIVATIVES, PREPARATION METHOD AND APPLICATION | September 2020 | March 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 16982281 | TOPICAL COMPOSITION | September 2020 | October 2022 | Allow | 25 | 2 | 1 | Yes | No |
| 17000995 | VAP-1 INHIBITORS FOR TREATING PAIN | August 2020 | May 2024 | Abandon | 44 | 2 | 1 | No | No |
| 16999368 | HYDROPHILIC GEL FOR TOPICAL DELIVERY OF 5-AMINOLEVULINIC ACID | August 2020 | September 2023 | Allow | 37 | 2 | 1 | Yes | No |
| 16947809 | PROCESS FOR INCREASING THE STABILITY OF A COMPOSITION COMPRISING POLYUNSATURATED OMEGA-3 FATTY ACIDS | August 2020 | June 2023 | Allow | 34 | 3 | 1 | Yes | No |
| 16990259 | ABUSE-DETERRENT COMPOSITIONS | August 2020 | June 2024 | Abandon | 46 | 4 | 0 | Yes | Yes |
| 16940102 | COMPOSITIONS OF BILE ACIDS AND PHENYLBUTYRATE COMPOUNDS | July 2020 | November 2022 | Allow | 28 | 4 | 0 | Yes | No |
| 16927678 | AMLODIPINE FORMULATIONS | July 2020 | December 2020 | Allow | 5 | 1 | 0 | No | No |
| 16927664 | AMLODIPINE FORMULATIONS | July 2020 | December 2020 | Allow | 5 | 1 | 0 | No | No |
| 16899952 | TOPICAL ACYCLOVIR FORMULATIONS AND USES THEREOF | June 2020 | September 2021 | Allow | 15 | 2 | 1 | Yes | No |
| 16898249 | TOPICAL PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST AMITRIPTYLINE, FOR THE TREATMENT OF PERIPHERAL NEUROPATHIC PAIN | June 2020 | February 2024 | Allow | 44 | 2 | 0 | Yes | No |
| 16896385 | SYSTEM AND METHOD FOR APPLYING TREATMENT TO A TREATMENT ZONE | June 2020 | August 2024 | Abandon | 50 | 3 | 1 | Yes | No |
| 16856363 | Topical Analgesic Compositions | April 2020 | June 2024 | Allow | 50 | 3 | 1 | Yes | No |
| 16855907 | DERMAL COMPOSITIONS | April 2020 | April 2023 | Allow | 36 | 1 | 1 | Yes | No |
| 16853380 | AMLODIPINE FORMULATIONS | April 2020 | October 2020 | Allow | 6 | 0 | 1 | Yes | No |
| 16840345 | Therapeutic Calcium Phosphate Particles in Use for Aesthetic or Cosmetic Medicine, and Methods of Manufacture and Use | April 2020 | January 2023 | Abandon | 33 | 1 | 0 | No | No |
| 16824496 | METHODS OF TREATMENT WITH DEUTERATED CFTR POTENTIATORS | March 2020 | October 2023 | Abandon | 43 | 1 | 1 | No | No |
| 16637777 | NASAL DECONGESTANT COMPOSITIONS COMPRISING DEXPANTHENOL AND SODIUM HYALURONATE | February 2020 | July 2023 | Abandon | 42 | 2 | 0 | No | No |
| 16774270 | CANNABIONID AND CANNABIS-BASED COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS OF THE GASTROINTESTINAL TRACT | January 2020 | November 2022 | Abandon | 34 | 0 | 1 | No | No |
| 16631205 | Photodynamic Therapy Method for Skin Disorders | January 2020 | November 2022 | Abandon | 34 | 1 | 1 | No | No |
| 16696110 | AR+ BREAST CANCER TREATMENT METHODS | November 2019 | June 2023 | Allow | 42 | 2 | 1 | Yes | No |
| 16673549 | PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE | November 2019 | September 2022 | Allow | 34 | 2 | 0 | Yes | No |
| 16608783 | TOPICAL PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST AMITRIPTYLINE, FOR THE TREATMENT OF PERIPHERAL NEUROPATHIC PAIN | October 2019 | June 2024 | Abandon | 56 | 4 | 1 | Yes | No |
| 16605785 | METHODS FOR DIAGNOSING AND TREATING CACHEXIA | October 2019 | March 2023 | Abandon | 41 | 2 | 1 | No | No |
| 16593677 | ANIMAL FEED COMPOSITIONS OF ABSCISIC ACID | October 2019 | September 2023 | Abandon | 47 | 5 | 0 | No | No |
| 16593190 | TOPICAL REGIONAL NEURO-AFFECTIVE THERAPY | October 2019 | July 2021 | Abandon | 22 | 1 | 0 | No | No |
| 16592340 | SHIKIMATE ANALOGUES AND METHODS OF USE | October 2019 | February 2022 | Abandon | 28 | 2 | 1 | No | No |
| 16586690 | TRANSPORE DELIVERY OF DRUGS AND USES THEREOF | September 2019 | January 2023 | Abandon | 40 | 1 | 1 | No | No |
| 16578002 | Reversal of General Anesthesia by Administration of Methylphenidate, Amphetamine, Modafinil, Amantadine, and/or Caffeine | September 2019 | March 2023 | Allow | 42 | 1 | 1 | Yes | No |
| 16547120 | OXYMETAZOLINE FOR THE TREATMENT OF ANO-RECTAL DISORDERS | August 2019 | March 2021 | Abandon | 18 | 2 | 0 | No | No |
| 16485544 | NANOEMULSION COMPRISING IMIDAZOQUINOLINE-BASED MATERIAL AND USE THEREOF | August 2019 | June 2023 | Abandon | 46 | 3 | 1 | No | No |
| 16537596 | PROCESS FOR PRODUCING A NANO-CBD MICROEMULSION SYSTEM | August 2019 | September 2022 | Allow | 38 | 1 | 1 | Yes | No |
| 16522853 | Method Of Manufacturing Fine Particles Suitable For Orally Disintegrating Pharmaceutical Dosage Forms | July 2019 | July 2020 | Abandon | 12 | 2 | 0 | No | No |
| 16448335 | IONIC LIQUIDS FOR TRANSDERMAL DRUG DELIVERY | June 2019 | May 2023 | Allow | 47 | 3 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SOROUSH, LAYLA.
With a 48.1% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 32.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SOROUSH, LAYLA works in Art Unit 1627 and has examined 754 patent applications in our dataset. With an allowance rate of 33.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 37 months.
Examiner SOROUSH, LAYLA's allowance rate of 33.6% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SOROUSH, LAYLA receive 2.55 office actions before reaching final disposition. This places the examiner in the 86% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by SOROUSH, LAYLA is 37 months. This places the examiner in the 13% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +55.9% benefit to allowance rate for applications examined by SOROUSH, LAYLA. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 10.6% of applications are subsequently allowed. This success rate is in the 2% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 24.2% of cases where such amendments are filed. This entry rate is in the 24% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 89.4% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 65% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 61.2% of appeals filed. This is in the 33% percentile among all examiners. Of these withdrawals, 48.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 46.6% are granted (fully or in part). This grant rate is in the 53% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 1.5% of allowed cases (in the 73% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.6% of allowed cases (in the 62% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.